Preliminary data indicated that IOA-289 is a novel ATX inhibitor with a unique chemical structure, high potency, and a good safety profile, thus supporting further new therapeutic approaches for cancer treatment, particularly those with a high fibrotic and immunologically cold phenotype (ClinicalTrials.gov ID NCT05586516). The gene discussed is ENPP2; the disease is cancer.